BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

878 related articles for article (PubMed ID: 30039219)

  • 1. A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication.
    Wei J; Yang G; Hao X; Gu D; Tan Y; Wang X; Dong D; Zhang S; Wang L; Zhang H; Tian J
    Eur Radiol; 2019 Feb; 29(2):877-888. PubMed ID: 30039219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiomics signature: A potential biomarker for the prediction of MGMT promoter methylation in glioblastoma.
    Xi YB; Guo F; Xu ZL; Li C; Wei W; Tian P; Liu TT; Liu L; Chen G; Ye J; Cheng G; Cui LB; Zhang HJ; Qin W; Yin H
    J Magn Reson Imaging; 2018 May; 47(5):1380-1387. PubMed ID: 28926163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fusion Radiomics Features from Conventional MRI Predict MGMT Promoter Methylation Status in Lower Grade Gliomas.
    Jiang C; Kong Z; Liu S; Feng S; Zhang Y; Zhu R; Chen W; Wang Y; Lyu Y; You H; Zhao D; Wang R; Wang Y; Ma W; Feng F
    Eur J Radiol; 2019 Dec; 121():108714. PubMed ID: 31704598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiregional radiomics features from multiparametric MRI for prediction of MGMT methylation status in glioblastoma multiforme: A multicentre study.
    Li ZC; Bai H; Sun Q; Li Q; Liu L; Zou Y; Chen Y; Liang C; Zheng H
    Eur Radiol; 2018 Sep; 28(9):3640-3650. PubMed ID: 29564594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A radiomics nomogram may improve the prediction of IDH genotype for astrocytoma before surgery.
    Tan Y; Zhang ST; Wei JW; Dong D; Wang XC; Yang GQ; Tian J; Zhang H
    Eur Radiol; 2019 Jul; 29(7):3325-3337. PubMed ID: 30972543
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Kong Z; Lin Y; Jiang C; Li L; Liu Z; Wang Y; Dai C; Liu D; Qin X; Wang Y; Liu Z; Cheng X; Tian J; Ma W
    Cancer Imaging; 2019 Aug; 19(1):58. PubMed ID: 31426864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The interplay mechanism between IDH mutation, MGMT-promoter methylation, and PRMT5 activity in the progression of grade 4 astrocytoma: unraveling the complex triad theory.
    Kurdi M; Alkhotani A; Sabbagh A; Faizo E; Lary AI; Bamaga AK; Almansouri M; Hafiz B; Alsharif T; Baeesa S
    Oncol Res; 2024; 32(6):1037-1045. PubMed ID: 38827324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Machine learning-based radiomic, clinical and semantic feature analysis for predicting overall survival and MGMT promoter methylation status in patients with glioblastoma.
    Lu Y; Patel M; Natarajan K; Ughratdar I; Sanghera P; Jena R; Watts C; Sawlani V
    Magn Reson Imaging; 2020 Dec; 74():161-170. PubMed ID: 32980505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Radiomics Analyses Based on Different Magnetic Resonance Imaging Sequences in Grading and Molecular Genomic Typing of Glioma.
    Huang WY; Wen LH; Wu G; Hu MZ; Zhang CC; Chen F; Zhao JN
    J Comput Assist Tomogr; 2021 Jan-Feb 01; 45(1):110-120. PubMed ID: 33475317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma.
    Wick A; Kessler T; Platten M; Meisner C; Bamberg M; Herrlinger U; Felsberg J; Weyerbrock A; Papsdorf K; Steinbach JP; Sabel M; Vesper J; Debus J; Meixensberger J; Ketter R; Hertler C; Mayer-Steinacker R; Weisang S; Bölting H; Reuss D; Reifenberger G; Sahm F; von Deimling A; Weller M; Wick W
    Neuro Oncol; 2020 Aug; 22(8):1162-1172. PubMed ID: 32064499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of
    Jovanović N; Mitrović T; Cvetković VJ; Tošić S; Vitorović J; Stamenković S; Nikolov V; Kostić A; Vidović N; Krstić M; Jevtović-Stoimenov T; Pavlović D
    Medicina (Kaunas); 2019 Feb; 55(2):. PubMed ID: 30717206
    [No Abstract]   [Full Text] [Related]  

  • 12. Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis.
    Han Y; Yan LF; Wang XB; Sun YZ; Zhang X; Liu ZC; Nan HY; Hu YC; Yang Y; Zhang J; Yu Y; Sun Q; Tian Q; Hu B; Xiao G; Wang W; Cui GB
    BMC Cancer; 2018 Feb; 18(1):215. PubMed ID: 29467012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
    Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
    Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
    Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X
    Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telomerase reverse transcriptase promoter mutation- and O
    Gramatzki D; Felsberg J; Hentschel B; Wolter M; Schackert G; Westphal M; Regli L; Thon N; Tatagiba M; Wick W; Schlegel U; Krex D; Matschke J; Roth P; Suresh MP; Kamp MA; Rushing EJ; Pietsch T; von Deimling A; Sabel M; Loeffler M; Weller M; Reifenberger G
    Eur J Cancer; 2021 Apr; 147():84-94. PubMed ID: 33631540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas.
    Ochsenbein AF; Schubert AD; Vassella E; Mariani L
    J Neurooncol; 2011 Jun; 103(2):343-51. PubMed ID: 20857319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
    Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y
    J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
    van den Bent MJ; Dubbink HJ; Sanson M; van der Lee-Haarloo CR; Hegi M; Jeuken JW; Ibdaih A; Brandes AA; Taphoorn MJ; Frenay M; Lacombe D; Gorlia T; Dinjens WN; Kros JM
    J Clin Oncol; 2009 Dec; 27(35):5881-6. PubMed ID: 19901104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different diagnostic values of imaging parameters to predict pseudoprogression in glioblastoma subgroups stratified by MGMT promoter methylation.
    Yoon RG; Kim HS; Paik W; Shim WH; Kim SJ; Kim JH
    Eur Radiol; 2017 Jan; 27(1):255-266. PubMed ID: 27048531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.